42:I[58016,["/_next/static/chunks/b5ea50e123aa84a6.js","/_next/static/chunks/5e17b2e37c80a96c.js","/_next/static/chunks/de880ec5a0241b38.js","/_next/static/chunks/48003610e91209eb.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/81ce7bf5f20dbd5a.js","/_next/static/chunks/53f751967ccc7d59.js","/_next/static/chunks/903c358828afe0bc.js","/_next/static/chunks/00da439d4db502cc.js","/_next/static/chunks/88bed98e5cd5e639.js"],"ProcessEpisodeButton"] 44:I[185,["/_next/static/chunks/b5ea50e123aa84a6.js","/_next/static/chunks/5e17b2e37c80a96c.js","/_next/static/chunks/de880ec5a0241b38.js","/_next/static/chunks/48003610e91209eb.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/81ce7bf5f20dbd5a.js","/_next/static/chunks/53f751967ccc7d59.js","/_next/static/chunks/903c358828afe0bc.js","/_next/static/chunks/00da439d4db502cc.js","/_next/static/chunks/88bed98e5cd5e639.js"],"SendEmailButton"] 45:I[45269,["/_next/static/chunks/b5ea50e123aa84a6.js","/_next/static/chunks/5e17b2e37c80a96c.js","/_next/static/chunks/de880ec5a0241b38.js","/_next/static/chunks/48003610e91209eb.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/81ce7bf5f20dbd5a.js","/_next/static/chunks/53f751967ccc7d59.js","/_next/static/chunks/903c358828afe0bc.js","/_next/static/chunks/00da439d4db502cc.js","/_next/static/chunks/88bed98e5cd5e639.js"],"SignupCTA"] 47:I[56939,["/_next/static/chunks/b5ea50e123aa84a6.js","/_next/static/chunks/5e17b2e37c80a96c.js","/_next/static/chunks/de880ec5a0241b38.js","/_next/static/chunks/48003610e91209eb.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/81ce7bf5f20dbd5a.js","/_next/static/chunks/53f751967ccc7d59.js","/_next/static/chunks/903c358828afe0bc.js","/_next/static/chunks/00da439d4db502cc.js","/_next/static/chunks/88bed98e5cd5e639.js"],"EpisodeTranscript"] 3c:["$","span",null,{"className":"inline-flex items-center gap-2 bg-secondary/50 px-3 py-1 rounded-full","children":[["$","svg",null,{"className":"w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M8 7V3m8 4V3m-9 8h10M5 21h14a2 2 0 002-2V7a2 2 0 00-2-2H5a2 2 0 00-2 2v12a2 2 0 002 2z"}]}],["$","time",null,{"dateTime":"2024-09-26T08:00:00.000Z","children":"Thu Sep 26 2024"}]]}] 43:T4c4,

The iconic brand Tupperware filed for bankruptcy this week, burdened with over $1.2 billion of debt. They’ve reached a point of no return, where digging out is virtually impossible. In many ways, this mirrors the struggle of those facing severe obesity—a situation where years of weight gain have led to a seemingly insurmountable challenge.

Just as companies can file for Chapter 11 and start afresh, people now have a potential reset button with the advent of weight loss drugs like semaglutide. In this week’s podcast, I’ll delve into this rapidly evolving landscape and what it could mean for those facing their own weight loss bankruptcy.

Listen and learn:

How diabetes drugs are being used for weight loss and why
Are diabetics missing out because of this trend?
What are the safety concerns and risks of these new drugs?
What happens when you stop using them?
The risks vs rewards of long-term use
Navigating the costs and practical considerations

Like the Show?

Leave us a review
Check out our YouTube channel

639: Weight Loss Bankruptcy with Lucas Rockwood